Increase in adoption of Medtronic plc‘s MDT globally-accepted advanced therapies is encouraging. The stock currently carries a Zacks Rank #3 (Hold).

Over the past three months, Medtronic has outperformed the industry. As per the last share-price movement, the stock has gained 5.5% as against the industry’s 1.5% depreciation.

Medtronic’s fourth-quarter fiscal 2021 earnings and revenues were both ahead of the respective Zacks Consensus Estimate. According to the company, most of the end markets are returning to near-normal pre-COVID growth. While some regions are still lagging due to the prevailing health crisis, momentum built strongly throughout the fourth quarter.

Medtronic’s fiscal fourth-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in April 2020. The company continued to gain share in an increasing number of businesses, driven by…

Read more…

Share.

Comments are closed.